We are live on ! Find out more
ONCE

Spark Therapeutics, Inc. Common Stock
ONCE

Delisted

ONCE was delisted on the 16th of December, 2019.

162 hedge funds and large institutions have $2.57B invested in Spark Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 50 increasing their positions, 50 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more capital invested

Capital invested by funds: $1.92B → $2.57B (+$649M)

30% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 27

1% more funds holding

Funds holding: 160162 (+2)

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

0% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 50

13% less call options, than puts

Call options by funds: $21.8M | Put options by funds: $25.2M

Holders
162
Holders Change
+2
Holders Change %
+1.25%
% of All Funds
3.71%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
35
Increased
50
Reduced
50
Closed
27
Calls
$21.8M
Puts
$25.2M
Net Calls
-$3.36M
Net Calls Change
-$19.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$359M -$9.05M -156,680 -3%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$260M -$12.5M -217,093 -5%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$252M +$38.3M +663,671 +21%
Vanguard Group
4
Vanguard Group
Pennsylvania
$176M +$3.75M +64,909 +3%
BlackRock
5
BlackRock
New York
$176M -$624K -10,812 -0.4%
JP Morgan Chase
6
JP Morgan Chase
New York
$161M +$10.1M +175,622 +8%
State Street
7
State Street
Massachusetts
$118M +$21.8M +377,801 +27%
Federated Hermes
8
Federated Hermes
Pennsylvania
$99.7M -$20.4M -353,612 -19%
BBA
9
Baker Bros. Advisors
New York
$92.2M
ClearBridge Investments
10
ClearBridge Investments
New York
$45.8M -$8.84K -153 -0%
PHS
11
PFM Health Sciences
California
$42.5M +$36.8M +637,636 New
RSCM
12
Rock Springs Capital Management
Maryland
$41.5M +$491K +8,500 +1%
Janus Henderson Group
13
Janus Henderson Group
United Kingdom
$39.2M -$25.5M -442,223 -43%
GPP
14
Great Point Partners
Connecticut
$36.6M +$8.03M +139,100 +34%
GGHC
15
Gilder Gagnon Howe & Co
New York
$35.4M -$920K -15,930 -3%
SI
16
Sofinnova Investments
California
$32M +$27.8M +481,270 New
CC
17
Casdin Capital
New York
$30.8M +$9.27M +160,526 +53%
Macquarie Group
18
Macquarie Group
Australia
$29.6M +$15.5M +268,834 +153%
O
19
OppenheimerFunds
New York
$28.4M +$12M +207,316 +95%
Morgan Stanley
20
Morgan Stanley
New York
$25.9M +$12.6M +217,978 +127%
Rockefeller Capital Management
21
Rockefeller Capital Management
New York
$23.9M +$20.8M +359,512 New
Capital World Investors
22
Capital World Investors
California
$23M
Northern Trust
23
Northern Trust
Illinois
$22.6M +$216K +3,743 +1%
Lord, Abbett & Co
24
Lord, Abbett & Co
New Jersey
$20.2M +$344K +5,957 +2%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$19.6M +$1.02M +17,747 +6%

ONCE Hedge Fund Activity: Q1 2018 in Review

162 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q1 2018, worth a combined $2.57B — up 34% from $1.92B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ONCE positions and 27 closed out — a net gain of 8 holders — while 50 added to existing stakes and 50 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $38.3M. The largest seller was Janus Henderson Group, cutting an estimated $25.5M.

  • 162 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q1 2018, up from 160 in Q4 2017.
  • Funds reported $2.57B of Spark Therapeutics, Inc. Common Stock stock for Q1 2018, up 34% quarter-over-quarter.
  • 35 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q1 2018 and 27 closed out, a net change of +8 holders.
  • The largest Spark Therapeutics, Inc. Common Stock buyer in Q1 2018 was Wellington Management Group, an estimated $38.3M added.
  • The largest Spark Therapeutics, Inc. Common Stock seller in Q1 2018 was Janus Henderson Group, an estimated $25.5M sold.

Based on aggregated 13F filings for Q1 2018.